Thomas G Todaro Selected Research

pexelizumab

3/2012	Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction.
7/2011	Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials.
3/2010	Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction.
11/2009	Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
4/2009	Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
9/2008	ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
12/2007	Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI.
1/2007	Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.
9/2006	Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.
8/2006	Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas G Todaro Research Topics

Disease

18	Myocardial Infarction 07/2011 - 09/2003
8	Infarction (Infarctions) 03/2012 - 09/2003
8	ST Elevation Myocardial Infarction 03/2010 - 09/2003
5	Heart Failure 04/2009 - 09/2003
4	Shock 11/2009 - 09/2003
4	Inflammation (Inflammations) 11/2008 - 03/2004
2	Reperfusion Injury 09/2006 - 05/2004
1	Colorectal Neoplasms (Colorectal Cancer) 01/2016
1	Neoplasms (Cancer) 01/2016
1	Type 2 Diabetes Mellitus (MODY) 01/2015
1	Cardiac Arrhythmias (Arrythmia) 03/2012
1	Cardiogenic Shock 04/2009
1	Thrombosis (Thrombus) 11/2008
1	Ischemia 08/2006
1	Diabetes Mellitus 08/2006
1	Left Ventricular Dysfunction 03/2004
1	Infections 09/2003
1	Stroke (Strokes) 09/2003
1	Myocardial Ischemia (Ischemic Heart Diseases) 09/2003

Drug/Important Bio-Agent (IBA)

16	pexelizumabIBA 03/2012 - 09/2003
8	Complement System Proteins (Complement)IBA 03/2012 - 09/2003
7	Complement C5 (Complement 5)IBA 07/2011 - 09/2003
4	Creatine Kinase (Creatine Phosphokinase)IBA 03/2012 - 03/2004
3	Biomarkers (Surrogate Marker)IBA 04/2009 - 09/2008
3	MB Form Creatine KinaseIBA 09/2008 - 09/2003
2	Monoclonal AntibodiesIBA 01/2007 - 09/2003
1	trifluridine tipiracil drug combinationIBA 01/2016
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2015
1	N(2)-(3-trifluoromethylphenyl)guanineIBA 11/2009
1	Troponin IIBA 09/2008
1	Glucose (Dextrose)FDA LinkGeneric 06/2006
1	Protein Isoforms (Isoforms)IBA 03/2004
1	Pharmaceutical PreparationsIBA 09/2003

Therapy/Procedure

6	Percutaneous Coronary Intervention 03/2012 - 09/2003
6	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 07/2011 - 03/2004
5	Therapeutics 01/2015 - 09/2003
3	Cardiopulmonary Bypass (Heart-Lung Bypass) 08/2006 - 03/2004
1	Drug Therapy (Chemotherapy) 03/2012
1	Thrombolytic Therapy 03/2012
1	Intravenous Administration 01/2007